<unk> , sold under the brand name Retevmo, is a medication for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET or "rearranged during transfection"). It is taken by mouth. The most common side effects include changes in laboratory tests (including increased liver enzymes, increased blood sugar, decreased white cell and platelet counts, decreased protein level, decreased calcium, increased total cholesterol, increased creatinine, and decreased sodium) dry mouth, diarrhea, high blood pressure, fatigue, edema, rash, and constipation.<unk>  is a kinase inhibitor, meaning it blocks a type of enzyme (kinase) and helps prevent the cancer cells from growing. Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing.<unk>  is the first therapy approved specifically for people with cancer and the RET gene alterations.
Selpercatinib
Tucatinib
Fostamatinib
Brigatinib
Neratinib
Capmatinib
Infigratinib
Lapatinib